GPR30 gene polymorphisms are associated with progesterone receptor status and histopathological characteristics of breast cancer patients

Journal of Steroid Biochemistry and Molecular Biology

Volumn 118, Issue 1-2, 2010, Pages 7-12

  Giess, Maria ^a   Lattrich, Claus ^a   Springwald, Anette ^a   Goerse, Regina ^a   Ortmann, Olaf ^a   Treeck, Oliver ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Breast cancer; GPR30 gene; Progesterone receptor

Indexed keywords

G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 30; GLYCINE; LEUCINE; PROGESTERONE RECEPTOR; PROLINE;

5' UNTRANSLATED REGION; ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; POLYMERASE CHAIN REACTION; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GROWTH; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PROGESTERONE; YOUNG ADULT;

TETRA;

EID: 72449174718     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.09.001     Document Type: Article

References (34)

1. Carmeci C., Thompson D.A., et al. Identification of a Gene (GPR30) with Homology to the G-protein-coupled Receptor Superfamily Associated with Estrogen Receptor Expression in Breast Cancer (1997), Academic Press
2. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., and Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signalling. Science 307 Mar (5715) (2005) 1625-1630
3. Filardo E.J., Quinn J.A., et al. Estrogen-induced activation of Erk-1 and Erk-2 requires the G-protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 14 10 (2002) 1649-1660
4. Bologa C.G., Revankar C.M., Young S.M., Edwards B.S., Arterburn J.B., Kiselyov A.S., Parker M.A., Tkachenko S.E., Savchuck N.P., Sklar L.A., Oprea T.I., and Prossnitz ER. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol. 2 4 (2006) 207-212
5. Albanito L., Madeo A., Lappano R., Vivacqua A., Rago V., Carpino A., Oprea T.I., Prossnitz E.R., Musti A.M., Andò S., and Maggiolini M. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 67 February (4) (2007) 1859-1866
6. Otto C., Rohde-Schulz B., Schwarz G., Fuchs I., Klewer M., Brittain D., Langer G., Bader B., Prelle K., Nubbemeyer R., and Fritzemeier K.H. G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology 149 10 (2008) 4846-4856
7. Pedram A., Razandi M., and Levin E.R. Nature of functional estrogen receptors at the plasma membrane. Mol. Endocrinol. 20 9 (2006) 1996-2009
8. Pandey D.P., Lappano R., Albanito L., Madeo A., Maggiolini M., and Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J. 28 March (5) (2009) 523-532
9. Kleuser B., Malek D., Gust R., Pertz H.H., and Potteck H. 17-Beta-estradiol inhibits transforming growth factor-beta signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30. Mol. Pharmacol. 74 6 (2008) 1533-1543
10. Price D.T., and Ridker P.M. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann. Intern. Med. 127 November (10) (1997) 895-903
11. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., and Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 August (5123) (1993) 921-923
12. Loréal O., Ropert M., Mosser A., Déhais V., Deugnier Y., David V., Brissot P., and Jouanolle A.M. Pathophysiology and genetics of classic HFE (type 1) hemochromatosis. Presse Med. 36 9 Pt 2 (2007) 1271-1277
13. Poonkuzhali B., Lamba J., Strom S., Sparreboom A., Thummel K., Watkins P., and Schuetz E. Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms. Drug Metab. Dispos. 36 4 (2008) 780-795
14. Thomas G., et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat. Genet. 41 5 (2009) 579-584
15. Ahmed S., et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat. Genet. 41 5 (2009) 585-590
16. Gold B., et al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc. Natl. Acad. Sci. U.S.A. 105 March (11) (2008) 4340-4345
17. Hunter D.J., et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39 July (7) (2007) 870-874 (Epub 2007 May 27)
18. Easton D.F., et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447 June (7148) (2007) 1087-1093
19. Lind J.M., Chiu C., Ingles J., Yeates L., Humphries S.E., Heather A.K., and Semsarian C. Sex hormone receptor gene variation associated with phenotype in male hypertrophic cardiomyopathy patients. J. Mol. Cell Cardiol. 45 2 (2008) 217-222
20. Domingues-Montanari S., Subirana I., Tomás M., Marrugat J., and Sentí M. Association between ESR2 genetic variants and risk of myocardial infarction. Clin. Chem. 54 7 (2008) 1183-1189
21. Nilsson M., Dahlman I., Jiao H., Gustafsson J.A., Arner P., and Dahlman-Wright K. Impact of estrogen receptor gene polymorphisms and mRNA levels on obesity and lipolysis-a cohort study. BMC Med. Genet. 8 December (2007) 73
22. Siddig A., Mohamed A.O., Awad S., Hassan A.H., Zilahi E., Al-Haj M., Bernsen R., and Adem A. Estrogen receptor alpha gene polymorphism and breast cancer. Ann. N. Y. Acad. Sci. 1138 (2008) 95-107
23. Zheng W., Long J., Gao Y.T., Li C., Zheng Y., Xiang Y.B., Wen W., Levy S., Deming S.L., Haines J.L., Gu K., Fair A.M., Cai Q., Lu W., and Shu X.O. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat. Genet. 41 3 (2009) 324-328
24. Fernández L.P., Milne R.L., Barroso E., Cuadros M., Arias J.I., Ruibal A., Benítez J., and Ribas G. Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk: a Spanish case-control study. Int. J. Cancer 119 July (2) (2006) 467-471
25. Ye S., Dhillon S., Ke X., Collins A.R., and Day I.N. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 29 17 (2001) E88-E188
26. The International HapMap Consortium. The International HapMap Project. Nature 426 6968 (2003) 789-796
27. Filardo E.J., Quinn J.A., and Sabo E. Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor. Steroids 73 9-10 (2008) 870-873
28. Albanito L., Sisci D., Aquila S., Brunelli E., Vivacqua A., Madeo A., Lappano R., Pandey D.P., Picard D., Mauro L., Andò S., and Maggiolini M. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology 149 8 (2008) 3799-3808
29. Filardo E.J., Graeber C.T., Quinn J.A., Resnick M.B., Giri D., DeLellis R.A., Steinhoff M.M., and Sabo E. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin. Cancer Res. 12 21 (2006)
30. Kuo W.H., Chang L.Y., Liu D.L., Hwa H.L., Lin J.J., Lee P.H., Chen C.N., Lien H.C., Yuan R.H., Shun C.T., Chang K.J., and Hsieh F.J. The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population. Taiwan J. Obstet. Gynecol. 46 2 (2007) 135-145
31. Liu S., Chia S.K., Mehl E., Leung S., Rajput A., Cheang M.C., and Nielsen T.O. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res. Treat. February (2009)
32. Lapidus R.G., Nass S.J., and Davidson N.E. The loss of estrogen and progesterone receptor gene expression in human breast cancer. J. Mammary Gland Biol. Neoplasia 3 1 (1998) 85-94
33. Meikle A., Garófalo E.G., Rodríguez-Piñón M., Tasende C., and Sahlin L. Regulation by gonadal steroids of estrogen and progesterone receptors along the reproductive tract in female lambs. Acta Vet. Scand. 42 1 (2001) 161-169
34. Albanito L., Lappano R., Madeo A., Chimento A., Prossnitz E.R., Cappello A.R., Dolce V., Abonante S., Pezzi V., and Maggiolini M. G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells. Environ. Health Perspect. 116 December (12) (2008) 1648-1655 (Epub 2008 Jul 22)